Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Sandoz Group Ltd ( (CH:SDZ) ) is now available.
Sandoz has launched generic rivaroxaban in Germany, providing a comprehensive range of film-coated tablets in 10 mg, 15 mg, and 20 mg strengths. This launch follows successful litigation challenging a dosage patent, allowing Sandoz to offer a high-quality, affordable alternative to Xarelto® and expand access to anticoagulant therapies. The launch is expected to enhance Sandoz’s market position in Germany and support affordability and access for patients and payers.
The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF55.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.
More about Sandoz Group Ltd
Sandoz is a global leader in generic and biosimilar medicines, headquartered in Basel, Switzerland. With a history dating back to 1886, the company offers a wide portfolio of approximately 1,300 products addressing various diseases, from common colds to cancer. Sandoz employs over 20,000 people from 100 nationalities and recorded net sales of USD 10.4 billion in 2024.
Average Trading Volume: 943,285
Technical Sentiment Signal: Buy
Current Market Cap: CHF21.96B
For an in-depth examination of SDZ stock, go to TipRanks’ Overview page.